罗欣药业(002793.SZ)：2025年中报净利润为1769.50万元

Financial Performance - The company's total revenue for the first half of 2025 was 1.077 billion yuan, a decrease of 182 million yuan compared to the same period last year, representing a year-on-year decline of 14.45% [1] - The net profit attributable to shareholders was 17.695 million yuan, ranking 86th among disclosed peers [1] - The net cash inflow from operating activities was 218 million yuan [1] Financial Ratios - The latest debt-to-asset ratio was 61.94%, ranking 116th among disclosed peers, an increase of 6.71 percentage points compared to the same period last year [3] - The latest gross profit margin was 50.16% [3] - The return on equity (ROE) was 1.25%, ranking 85th among disclosed peers [3] Earnings and Turnover - The diluted earnings per share were 0.02 yuan, ranking 89th among disclosed peers [4] - The total asset turnover ratio was 0.26 times [4] - The inventory turnover ratio was 1.24 times, a decrease of 0.30 times compared to the same period last year, representing a year-on-year decline of 19.54% [4] Shareholder Structure - The number of shareholders was 36,500, with the top ten shareholders holding 558 million shares, accounting for 51.30% of the total share capital [4] - The largest shareholder, Shandong Luoxin Holdings Co., Ltd., held 21.79% of the shares [4]